

Supplementary Table S1. Comparison of demographics, immunological measures of CMV, biomarkers and vascular health in RTR with and without detectable CMV DNA.

<i>A</i>		<i>B</i>		<i>A v B</i>	<i>C</i>	<i>D</i>	<i>C v D</i>
Saliva CMV DNA Positive RTR (n = 11)	Saliva CMV DNA Negative RTR (n = 71)	<i>p</i> - Value ^a	Plasma CMV DNA Positive RTR (n = 16)	Plasma CMV DNA Negative RTR (n = 61)	<i>p</i> - Value ^a		
Demographics							
Age (years)	58 (31–76)	57 (31–73)	0.50	59 (31–76)	64 (31–73)	0.67	
Male/ Female	7/4	39/32	0.75 ^b	12/4	32/29	0.16 ^b	
Immunological measures of CMV							
CMV Seropositive	10 (91%)	59 (83%)		16 (100%)	53 (87%)		
CMV Seronegative	1 (9%)	12 (17%)		0 (0%)	8 (13%)		
CMV lysate antibodies (AU)	797 (1–5582)	554 (0–7611)	0.26	810 (76–5582)	597 (0–7611)	0.19	
gB antibodies (AU)	527 (0–2932)	231 (0–2035)	0.009	414 (144–2932)	238 (0–2035)	0.006	
IE-1 antibodies (AU)	90 (17–1446),	98 (5–4775)	0.10	128 (5–4775)	99 (12–3646)	0.44	
CMV lysate T-cells ^c	63 (0–938), n = 9	60 (0–2077), n = 56	0.99	63 (0–938), n = 13	139 (0–2077), n = 47	0.86	
IE-1 pooled peptides T-cells ^c	210 (1–1533), n = 9	50 (0–1888), n = 55	0.14	210 (10–1533), n = 13	54.5 (0–1888), n = 46	0.04	
VLE peptide T-cells ^c	184 (0–1160), n = 6	1 (0–693), n = 27	0.02	184 (0–1160), n = 6	2 (0–693), n = 27	0.16	
pp65 pooled peptides T-cells ^c	283 (0–1989), n = 9	358 (0–1963), n = 56	0.93	666 (0–1989), n = 13	361 (0–1963), n = 47	0.22	
NLV peptide T-cells ^c	821 (10–1336), n = 5	22 (0–1896), n = 27	0.03	487 (0–985), n = 5	50 (0–1896), n = 27	0.54	
V δ 2- γ δ T-cells ^d	4.23 (0.19–14.30), n = 11	1.17 (0.06–17.50), n = 69	0.013	4.23 (0.26–14.30), n = 15	1.19 (0.07–17.50), n = 60	0.005	
Inflammatory Biomarkers							
sTNFR1, pg/mL	9065 (6062–14385)	3431 (410–33000)	0.63	9219 (4349–20447)	3411 (410–33000)	0.35	
sCD14, ng/mL	2137 (1623–2546)	2032 (1384–3640)	0.97	2063 (1487–813)	2040 (1384–3640)	0.56	
CRP, μ g/mL	1.89 (0.05–13.38)	1.47 (0.12–20.22)	0.55	2.45 (0.05–13.38)	1.47 (0.12–20.22)	0.36	
Vascular Biomarkers							
VCAM-1, ng/mL	498 (317–719)	439 (249–1143)	0.27	533 (317–727)	431 (264–1143)	0.03	
ICAM-1, ng/mL	153 (86–182)	133 (89–330)	0.20	164 (86–205)	133 (89–330)	0.08	
P-selectin, ng/mL	39 (27–78)	53 (28–107)	0.010	39 (27–83)	52 (28–107)	0.010	
Assessments of Vascular Health							
FMD	3.2 (0.1–5.1), n = 10	4.2 (0–15.8), n = 61	0.087	3.2 (0.1–5.1), n = 15	4.4 (0–15.8), n = 52	0.062	
Left cIMT (mm)	0.63 (0.45–0.95), n = 10	0.66 (0.44–1.30), n = 63	0.80	0.63 (0.45–0.95), n = 15	0.82 (0.44–1.30), n = 54	0.75	
Right cIMT (mm)	0.61 (0.43–0.91), n = 10	0.65 (0.45–1.33), n = 63	0.67	0.61 (0.43–1.0), n = 15	0.75 (0.45–1.33), n = 54	0.52	

^a Mann-Whitney test shown as median (range), ^b Fisher's exact test, ^c expressed as IFN γ spot forming units per 200,000 cells, ^d expressed as a % of CD3 T-cells